David Planchard: Neoadjuvant and adjuvant treatments for lung cancer to optimize patients’ survival

David Planchard, Thoracic Oncologist and Professor at the University Paris Saclay, posted on LinkedIn:

“So many questions about neoadjuvant/adjuvant treatments (IO, TKI, ADC…) for lung cancer and the use of biomarkers (MRD, NGS, pCR…) to optimize our treatments and our patients’ survival.

Panel discussion here in NY!”